Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 5, 2012, Pages 2119-2124

  Kim, Junwon ^a   Park, Changmin ^a   Ok, Taedong ^a   So, Wonyoung ^a   Jo, Mina ^a   Seo, Minjung ^a   Kim, Youngmi ^a   Sohn, Jeong Hun ^a   Park, Youngsam ^b   Ju, Moon Kyeong ^b   Kim, Junghwan ^b   Han, Sung Jun ^b   Kim, Tae Hee ^b   Cechetto, Jonathan ^b   Nam, Jiyoun ^b   Sommer, Peter ^b   No, Zaesung ^a  

^a Institute Pasteur Korea   (South Korea)

^b Institut Pasteur Korea   (South Korea)

Author keywords

3,4 Dihydropyrimidin 2(1H) one; Biginelli reaction; Enantiomers; Fractional crystallization; HIV

Indexed keywords

3,4 DIHYDROPYRIMIDIN 2(1H) ONE; GREEN FLUORESCENT PROTEIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTALLIZATION; DRUG DETERMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENANTIOMER; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; PYRIMIDINONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862803229     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.12.090     Document Type: Article

References (33)

1. H. Xu, and M. Lv Curr. Pharm. Des. 15 2009 2120
2. Y. Mehellou, and E. De Clercq J. Med. Chem. 53 2010 521 and references therein
3. B. Brenner, M.A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R.P. Sekaly, B. Conway, and J.P. Routy Int. J. Antimicrob. Agents 16 2000 429
4. A. Si-Mohamed, M. Kazatchkine, I. Heard, C. Goujon, T. Prazuck, G. Aymard, G. Cessot, Y.H. Kuo, M.C. Bernard, B. Diquet, J.E. Malkin, L. Gutmann, and L. Belec J. Infect. Dis. 182 2000 112
5. S. Kiertiburanakul, and S. Sungkanuparph Curr. HIV Res. 7 2009 273
6. A.M.J. Wensing, D.A. van de Vijver, and G. Angarano J. Infect. Dis. 192 2005 1501
7. F. Luque, R. Oya, D. Macias, and L. Saniger Cell. Mol. Biol. 51 2005 93
8. D. von Laer, S. Hasselmann, and K. Hasselmann J. Gene Med. 8 2006 658
9. D.B. Shinde, and R.R. Nagawade J. Heterocycl. Chem. 47 2010 33
10. K. Pandiarajan, S. Chitra, and D. Devanathan Eur. J. Med. Chem. 45 2010 367
11. T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Schreiber, and T.J. Mitchison Science 286 1999 971
12. S.J. Haggarty, T.U. Mayer, D.T. Miyamoto, R. Fathi, R.W. King, T.J. Mitchison, and S.L. Schreiber Chem. Biol. 7 2000 275
13. D. Russowsky, R.F.S. Canto, S.A.A. Sanches, M.G.M. D'Oca, A. de Fatima, R.A. Pilli, L.K. Kohn, M.A. Antonio, and J.E. de Carvalho Bioorg. Chem. 34 2006 173
14. H.A. Stefani, C.B. Oliveira, R.B. Almeida, C.M.P. Pereira, R.C. Braga, R. Cella, V.C. Borges, L. Savegnago, and C.W. Nogueira Eur. J. Med. Chem. 41 2006 513
15. One patent covering related dihydropyrimidinone compounds with anti-HIV activity was disclosed during our studies: Andrews, C. W.; Cao, P.; Freeman, G. A.; Qu, J. 2009, WO 2009020457.
16. P. Biginelli Gazz. Chim. Ital. 23 1893 360
17. K. Folkers, H.J. Harwood, and T.B. Johnson J. Am. Chem. Soc. 54 1932 3751
18. For a review of the Biginelli reaction, see: C.O. Kappe Tetrahedron 49 1993 6937
19. G. Sartori, F. Bigi, S. Carloni, B. Frullanti, and R. Maggi Tetrahedron Lett. 40 1999 3465
20. J. Lu, Y.J. Bai, Z.J. Wang, B.Q. Yang, and H.R. Ma Tetrahedron Lett. 41 2000 9075
21. E.H. Hu, D.R. Sidler, and U.H. Dolling J. Org. Chem. 63 1998 3454
22. C.O. Kappe, and S.F. Falsone Synlett 1998 718
23. C.O. Kappe, D. Kumar, and R.S. Varma Synthesis 1999 1799
24. B.C. Ranu, A. Hajra, and U. Jana J. Org. Chem. 65 2000 6270
25. 2, n-Hexanes/EtOAc/AcOH, 50:50:0.5) to afford the desired dihydropyrimidinone compound.
26. K. Mori, and H. Kisida Tetrahedron 42 1986 5281
27. S.P. Chavan, R.R. Kale, K. Shivasankar, S.I. Chandake, and S.B. Benjamin Synthesis 2003 2695
28. F. Szemes, T. Marchalin, N. Pronayova, and A. Daich Heterocycles 59 2003 779
29. 2. Fluorescence intensities were the determined using a multilabel plate reader (Victor3; PerkinElmer, Inc.; U.S.A.). And see Sommer, P.; Vartanian, J. P.; Wachsmuth, M.; Henry, M.; Guetard, D.; Wain-Hobson, S. J. Mol. Biol. 2004, 344, 11.
30. Enantiomerically pure forms were obtained by chiral HPLC (Daicel Chiralcel AD column).
31. D. Kontrec, V. Vinkovic, V. Sunjic, B. Schuiki, W.M. Fabian, and C.O. Kappe Chirality 15 2003 550
32. G. Uray, P. Verdino, F. Belaj, C.O. Kappe, and W.M. Fabian J. Org. Chem. 66 2001 6685
33. W. Krenn, P. Verdino, G. Uray, K. Faber, and C.O. Kappe Chirality 11 1999 659